Mindbloom, an innovative leader in the mental health industry, is revolutionizing the way patients can receive care by offering At-Home Psychedelic Therapy. Founded in 2018 and headquartered in the United States, the company specializes in guided at-home ketamine therapy, a cutting-edge approach heralded for its transformative potential in mental wellness. By collaborating with top medical professionals, Mindbloom has developed a premier treatment program that promises significant outcomes for its clients.
With a track record of accolades, including being listed among the Top 150 Digital Health Startups by CB Insights, the company is recognized for its strong organizational culture and leadership. Despite the last known investment occurring on 01 September 2020, Mindbloom boasts backing from top-tier venture capitalists, indicating a solid foundation for future growth. As the company strives to transform lives through its pioneering therapy services, it remains vigilant about maintaining client security, ensuring correspondence comes only from official channels.